Published online Nov 24, 2026. doi: 10.5306/wjco.124935
Revised: August 14, 2026
Accepted: October 22, 2026
Published online: November 24, 2026
Processing time: 142 Days and 16.9 Hours
Postoperative recurrence and metastasis significantly hinder long-term survival in colorectal cancer (CRC), with varied responses to adjuvant chemotherapy observ
To characterize the expression pattern and oncogenic function of HN1 L in CRC, investigate its association with Hippo signaling, and explore its association with postoperative risk stratification and adjuvant chemotherapy selection.
HN1 L expression and clinical relevance were assessed using transcriptomic and clinical data from The Cancer Genome Atlas, single-cell RNA sequencing data from GSE132465, immunohistochemical (IHC) analyses of 84 paraffin-embedded CRC specimens, and an independent cohort comprising 10 paired frozen CRC and adjacent normal tissues for Western blot (WB). Stable HN1 L-overexpressing and knockdown CRC cell lines underwent quantitative real-time polymerase chain reaction, WB, RNA sequencing, pathway enrichment analysis, as well as proliferation and migration assays. In vivo tumor-promoting effects of HN1 L were evaluated using xenograft models and IHC. Kaplan-Meier analysis, time-dependent receiver operating characteristic curves, Cox regression, and HN1 L expression-by-chemotherapy interaction analysis were utilized to examine clinical associations.
HN1 L exhibited upregulation in CRC, predominantly within tumor epithelial cells. Its overexpression augmented proliferation and migration, while knockdown induced the opposite effects. Endpoint xenograft outcomes and Ki-67 staining further corroborated its tumor-promoting role in vivo. Mechanistically, HN1 L diminished MOB1 and YAP phosphorylation, particularly at YAP Ser127 and Ser397, while elevating SNAIL expression, with overall YAP levels remaining largely unchanged. In the clinical cohort, baseline characteristics were generally consistent between HN1 L-high and HN1 L-low groups. High HN1 L expression correlated with reduced five-year overall survival (60% 95%CI: 34%-100% vs 96% 95%CI: 87%-100%, log-rank P = 0.039). Among HN1 L-high patients, the five-year disease-free survival (DFS) was 92% with adjuvant chemotherapy compared to 52% without. A significant HN1 L-by-chemotherapy interaction was noted for DFS (interaction hazard ratio = 0.09, 95%CI: 0.008-0.901; P = 0.031).
HN1 L promotes CRC progression by suppressing Hippo pathway activity. Elevated HN1 L expression correlates with poorer clinical outcomes and differential adjuvant chemotherapy benefit in this retrospective cohort, thereby supporting its potential role in CRC risk stratification and treatment selection.
Core Tip: This study identifies HN1 L as an oncogenic regulator in colorectal cancer (CRC). Integrated transcriptomic, cellular, xenograft, and clinical analyses demonstrate that HN1 L enhances CRC proliferation and migration by inhibiting Hippo pathway activity, primarily through reduced MOB1 and YAP phosphorylation. Clinically, high HN1 L expression was associated with poorer five-year overall survival, while an exploratory interaction analysis suggested a possible difference in adjuvant chemotherapy benefit according to HN1 L expression. These findings suggest that HN1 L may function as a chemotherapy-response indicator and a potential therapeutic target in CRC.